MARKET

INVA

INVA

Innoviva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.87
+0.12
+0.94%
After Hours: 12.87 0 0.00% 16:22 05/14 EDT
OPEN
12.79
PREV CLOSE
12.75
HIGH
12.89
LOW
12.73
VOLUME
489.15K
TURNOVER
--
52 WEEK HIGH
15.62
52 WEEK LOW
9.21
MARKET CAP
1.31B
P/E (TTM)
5.67
1D
5D
1M
3M
1Y
5Y
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be...
Benzinga · 2d ago
Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
– ATTACK Phase 3 topline data readout remains on track for second half of 2021 – – Strengthened balance sheet with $20M financing – WALTHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biophar...
GlobeNewswire · 05/05 20:05
A Look At Innoviva's (NASDAQ:INVA) Share Price Returns
Many investors define successful investing as beating the market average over the long term. But if you try your hand...
Simply Wall St. · 05/05 12:58
Entasis completes initial closing of $20M private placement with Innoviva
Clinical-stage biopharmaceutical company Entasis Therapeutics Holdings (ETTX) has completed the initial closing of an ~$7.5M stock and warrant issuance to a subsidiary of Innoviva (INVA). Upon satisfaction of certain closing conditions, Innoviva
Seekingalpha · 05/03 20:16
Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva
Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that it has completed the initial closing of an approximately $7.5 milli...
GlobeNewswire · 05/03 20:05
Alkermes reaches agreement with activist Sarissa to add board member
Biopharma company Alkermes (ALKS), which was targeted by activist investor Elliott Management last year, has reached an agreement with Sarissa Capital, giving the activist fund the right to designate a director
Seekingalpha · 04/30 13:28
Innoviva Stock Appears To Be Significantly Undervalued
GuruFocus News · 04/29 21:54
8-K: Innoviva, Inc.
(EDGAR Online via COMTEX) -- 0001080014 false 0001080014 2021-04-28 2021-04-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/28 23:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INVA. Analyze the recent business situations of Innoviva through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Underperform

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INVA stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 284
Institutional Holdings: 77.23M
% Owned: 76.16%
Shares Outstanding: 101.41M
TypeInstitutionsShares
Increased
39
3.41M
New
9
262.56K
Decreased
50
1.97M
Sold Out
17
308.27K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.42%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Independent Director
Odysseas Kostas
Chief Executive Officer
Pavel Raifeld
Chief Financial Officer
Richard Brand
Chief Accounting Officer
Marianne Zhen
Independent Director
George Bickerstaff
Independent Director
Deborah Birx
Independent Director
Mark DiPaolo
Independent Director
Mark Dipaolo
Independent Director
Jules Haimovitz
Independent Director
Sarah Schlesinger
Declaration Date
Dividend Per Share
Ex-Div Date
07/29/2015
Dividend USD 0.25
09/08/2015
--
Dividend USD 0.25
06/10/2015
02/23/2015
Dividend USD 0.25
03/10/2015
10/16/2014
Dividend USD 0.25
11/21/2014
08/06/2014
Dividend USD 0.25
08/26/2014
About INVA
Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Webull offers kinds of Innoviva Inc stock information, including NASDAQ:INVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INVA stock methods without spending real money on the virtual paper trading platform.